Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| NATIONAL HEALTHCARE CORPNHC · Entity 355 | Director | June 22, 2026 | June 23, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
NATIONAL HEALTHCARE CORP
Report date June 22, 2026 · Filed June 23, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Shares of Common StockSEC Table I · non-derivative | Direct | 65,595 |
Reported balance
After 2026-06-22 transaction · row 1
1 source rowRow 1 · 2026-06-22 · Sale · Disposed 5,937 · Balance 65,595 |
| Option to Purchase Common Stock [2022 Grant]SEC Table II · derivative / convertible security · Conversion / exercise price $69.19 · Expires 2027-05-04 | Direct | 7,500 |
Reported balance
Holding disclosure · report date 2026-06-22 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance 7,500 |
| Option to Purchase Common Stock [2023 Grant]SEC Table II · derivative / convertible security · Conversion / exercise price $55.75 · Expires 2028-05-03 | Direct | 7,500 |
Reported balance
Holding disclosure · report date 2026-06-22 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance 7,500 |
| Option to Purchase Common Stock [2024 Grant]SEC Table II · derivative / convertible security · Conversion / exercise price $96.03 · Expires 2029-05-08 | Direct | 7,500 |
Reported balance
Holding disclosure · report date 2026-06-22 · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · Balance 7,500 |
| Option to Purchase Common Stock [2025 Grant]SEC Table II · derivative / convertible security · Conversion / exercise price $94.66 · Expires 2030-05-07 | Direct | 7,500 |
Reported balance
Holding disclosure · report date 2026-06-22 · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · Balance 7,500 |
| Option to Purchase Common Stock [2026 Grant]SEC Table II · derivative / convertible security · Conversion / exercise price $171.42 · Expires 2031-05-06 | Direct | 7,500 |
Reported balance
Holding disclosure · report date 2026-06-22 · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · Balance 7,500 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 09, 2017 Filed May 10, 2017 18:05 UTC | NATIONAL HEALTHCARE CORP NHC · Entity 355 | GrantOption to Purchase Common Stock · Derivative | 7,500 | $0.00 Strike: $72.94 | $0.00 |
DisclosureSEC source: 0001047335-17-000104 · edgar.xml · derivative · entry 6 HASSAN EMIL E · CIK 0001288063 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 Underlying: Common Stock · 7,500 shares Expires 2022-05-08 F1 · shares: These stock options were granted pursuant to the Company's 2010 Omnibus Equity Incentive Plan on May 9, 2017. The grant and exercise of these stock options are exempt from Section 16(b) pursuant to Rule 16b-3(d). Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.